title: Avinza Elan.
abstract: Avinza is a once-daily morphine sulfate controlled-release formulation utilizing SODAS (Spheroidal Oral Drug Absorption System) technology developed by Elan and Ligand for the potential treatment of pain [220806], [223862]. This multiparticulate product is designed to provide a rapid onset of action together with a sustained therapeutic effect over 24 h. It is thought that once-daily administration should improve compliance and help eliminate breakthrough pain which is a feature of many twice-daily products, thereby providing better pain management [220806].
authors.affiliation: Marilyn.R.Semenchuk@gsk.com
authors.forename: Marilyn R
authors.initials: MR
authors.lastname: Semenchuk
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods / Q000706:statistics & numerical data; D003692:Delayed-Action Preparations / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004345:Drug Industry / Q000331:legislation & jurisprudence / Q000379:methods*; D006801:Humans; D009020:Morphine / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010146:Pain / Q000188:drug therapy
chemical_list: D003692:Delayed-Action Preparations; D009020:Morphine